NTLA · Intellia Therapeutics, Inc.
$11.91
+0.08 (+0.68%)
At close · Aug 14
Market Cap
$1.67B
Shares
140.13M
Intellia Therapeutics, Inc. Earnings Call Transcripts
Every quarterly earnings call for Intellia Therapeutics, Inc. (NTLA) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲114.2%
$14.03M
−$100.68M
'22 Q2
22-08-04
▲84.1%
$13.27M
−$113.23M
'22 Q3
22-11-03
▲5.6%
$13.57M
−$113.41M
'22 Q4
23-01-05
▲12%
$12.61M
−$103.13M
'23 Q1
23-05-04
▼3.1%
$13.59M
−$123.68M
'23 Q2
23-08-03
▼9.6%
$11.99M
−$122.22M
'23 Q3
23-11-09
▼114.1%
$
−$132.16M
'23 Q4
24-02-22
▲129.5%
$28.93M
−$107.44M
'24 Q1
24-05-09
▼48.8%
$6.96M
−$146.97M
'24 Q2
24-08-08
▼24%
$9.11M
−$135.71M
'24 Q3
24-11-07
·
$12.87M
−$128.90M
'24 Q4
25-01-10
▼42.5%
$16.63M
−$114.33M
'25 Q1
25-05-08
▲104.8%
$14.24M
−$101.25M
'25 Q2
25-08-07
▲51.3%
$13.78M
−$101.32M
'25 Q3
25-11-06
▲78.8%
$23.02M
−$95.79M
'25 Q4
26-02-26
LATEST
▼46.2%
$7.66M
−$106.63M
'26 Q2
26-08-06
Earnings call
FY26 · Q2
2026-08-06
Intellia Therapeutics Second Quarter 2026 Earnings Conference Call
Confident tone
NEXE in ATTR cardiomyopathy and polyneuropathy
Lombosi HALO Phase 3 results in HAE
HLA genotyping safety finding
Revenue
$7.66M
▼ 46.2% YoY Diluted EPS
$-0.80
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Intellia Therapeutics, Inc. Q4 FY2025 Earnings Call
Positive tone
HAE market research and demand
nex-z and MAGNITUDE clinical hold
lonvo-z / HAELO Phase 3 readout
Revenue
$23.02M*
▲ 78.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Intellia Therapeutics, Inc. Q3 FY2025 Earnings Call
Cautious tone
nex-z safety event and clinical hold
MAGNITUDE and MAGNITUDE-2 trials
lonvo-z (HAE) program progress
Revenue
$13.78M
▲ 51.3% YoY Diluted EPS
$-0.92
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Intellia Therapeutics, Inc. Q2 FY2025 Earnings Call
Confident tone
ATTR cardiomyopathy / nex-z (MAGNITUDE)
Enrollment acceleration & guidance update
Commercial / launch readiness
Revenue
$14.24M
▲ 104.8% YoY Diluted EPS
$-0.98
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Intellia Therapeutics, Inc. Q1 FY2025 Earnings Call
Confident tone
NTLA-2002 for HAE
Enrollment & Trial Timeline
Nexiguran Ziclumeran (Nex-Z) for ATTR
Revenue
$16.63M
▼ 42.5% YoY Diluted EPS
$-1.10
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-10
Intellia Therapeutics, Inc. Q4 FY2024 Earnings Call
Confident tone
Nex-z for ATTR amyloidosis with cardiomyopathy
Phase III enrollment progress
NTLA-2002 for hereditary angioedema (HAE)
Revenue
$12.87M*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Intellia Therapeutics, Inc. Q3 FY2024 Earnings Call
Confident tone
NTLA-2002 for Hereditary Angioedema (HAE)
NEX-Z (NTLA-2001) for ATTR Amyloidosis
Phase III trial execution and enrollment momentum
Revenue
$9.11M
▼ 24% YoY Diluted EPS
$-1.34
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Intellia Therapeutics, Inc. Q2 FY2024 Earnings Call
Confident tone
NTLA-2002 (HAE) pivotal program
NTLA-2001/NEX-Z (ATTR amyloidosis)
Commercialization preparation
Revenue
$6.96M
▼ 48.8% YoY Diluted EPS
$-1.52
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Intellia Therapeutics, Inc. Q1 FY2024 Earnings Call
Confident tone
ATTR program (NTLA-2001) and MAGNITUDE Phase III
Regulatory milestones and BLA
Pipeline expansion into new tissues
Revenue
$28.93M
▲ 129.5% YoY Diluted EPS
$-1.12
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-22
Intellia Therapeutics, Inc. Q4 FY2023 Earnings Call
Confident tone
NTLA-2001 / ATTR amyloidosis Phase 3 MAGNITUDE
NTLA-2002 / HAE program
Gene insertion platform
Revenue
$*
▼ 114.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Intellia Therapeutics, Inc. Q3 FY2023 Earnings Call
Revenue
$11.99M
▼ 9.6% YoY Diluted EPS
$-1.38
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Intellia Therapeutics, Inc. Q2 FY2023 Earnings Call
Revenue
$13.59M
▼ 3.1% YoY Diluted EPS
$-1.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Intellia Therapeutics, Inc. Q1 FY2023 Earnings Call
Revenue
$12.61M
▲ 12% YoY Diluted EPS
$-1.17
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-05
Intellia Therapeutics, Inc. Q4 FY2022 Earnings Call
Revenue
$13.57M*
▲ 5.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Intellia Therapeutics, Inc. Q3 FY2022 Earnings Call
Revenue
$13.27M
▲ 84.1% YoY Diluted EPS
$-1.49
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Intellia Therapeutics, Inc. Q2 FY2022 Earnings Call
Revenue
$14.03M
▲ 114.2% YoY Diluted EPS
$-1.33
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Intellia Therapeutics, Inc. Q1 FY2022 Earnings Call
Revenue
$11.25M
▲ 74.6% YoY Diluted EPS
$-1.96
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-01-06
Intellia Therapeutics, Inc. Q4 FY2021 Earnings Call
Revenue
$12.85M*
▲ 94.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Intellia Therapeutics, Inc. Q3 FY2021 Earnings Call
Revenue
$7.20M
▼ 67.6% YoY Diluted EPS
$-0.97
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Intellia Therapeutics, Inc. Q2 FY2021 Earnings Call
Revenue
$6.55M
▼ 59.7% YoY Diluted EPS
$-1.01
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Intellia Therapeutics, Inc. Q1 FY2021 Earnings Call
Revenue
$6.45M
▼ 50.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-01-07
Intellia Therapeutics, Inc. Q4 FY2020 Earnings Call
Revenue
$6.59M
▼ 39.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Intellia Therapeutics, Inc. Q3 FY2020 Earnings Call
Revenue
$22.22M
▲ 109.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Intellia Therapeutics, Inc. Q2 FY2020 Earnings Call
Revenue
$16.26M
▲ 46.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Intellia Therapeutics, Inc. Q1 FY2020 Earnings Call
Revenue
$12.92M
▲ 23.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-27
Intellia Therapeutics, Inc. Q4 FY2019 Earnings Call
Revenue
$10.94M
▲ 38.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–26 of 26 earnings calls
Key facts
CIK
1652130
CUSIP
45826J105
13F (30d)
334 filings
307 filers
Visit website
Investor relations